FDA Ordered To Reconsider Whether Braille-Free Label Meets ‘Same As’ Requirement
WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals held that a district court erred in part in rejecting Vanda Pharmaceuticals Inc.’s challenge to the U.S. Food and...To view the full article, register now.
Already a subscriber? Click here to view full article